Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GUSB | P08236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642652 | 0.90 | GAA (0.43) | GAAKDM4EHPGDGFERMEN1 | |
| SCHEMBL642282 | 0.89 | GAA (0.42) | GAAKDM4EHPGDGFERMEN1 | |
| SCHEMBL644706 | 0.89 | GAA (0.42) | GAAKDM4EHPGDGFERMEN1 | |
| SCHEMBL10106495 | 0.88 | GAA (0.45) | GAAKDM4EHPGDGFERMEN1 | |
| SCHEMBL642797 | 0.88 | GAA (0.41) | GAAKDM4EHPGDGFERMEN1 | |
| SCHEMBL10144863 | 0.86 | GAA (0.41) | GAAKDM4EHPGDGFERMEN1 | |
| SCHEMBL641652 | 0.86 | GAA (0.40) | GAAKDM4EHPGDGFERMEN1 | |
| SCHEMBL643211 | 0.86 | KDM4E (0.42) | GAAKDM4EHPGDGFERMEN1 | |
| SCHEMBL643030 | 0.86 | KDM4E (0.51) | GAAKDM4EHPGDGFERMEN1 | |
| SCHEMBL642075 | 0.86 | GAA (0.45) | GAAKDM4EHPGDGFERMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321739-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2016-04-26 | — | — | US | claimed |
| US-20110305666-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | RYS DAVID J (US) | 2011-12-15 | — | — | US | claimed |
| US-20050288345-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. | 2005-12-29 | — | — | US | claimed |
| EP-1539691-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004014317-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-02-19 | — | — | WO | claimed |
| US-9321739-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-8119672-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110305666-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | RYS DAVID J (US) | 2011-12-15 | — | — | US | disclosed |
| US-20050288345-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. | 2005-12-29 | — | — | US | disclosed |
| EP-1539691-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014317-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305666-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, PML | GAA 1534/4885KDM4E 4428/4885HPGD 1012/4885 |
| US-20050288345-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | TTPA, HAVCR2, PML | GAA 1534/4885KDM4E 4428/4885HPGD 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.